PMID: 21562063
It is not recommended for pregnant or breastfeeding women unless advised by a healthcare professional
Lancet Diabetes Endocrinol 8(5):392406 Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsbll T, Warren ML, Bain SC (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Semaglutida: informacin clave La semaglutida es un agonista del receptor del pptido similar al glucagn tipo 1 (GLP-1)
DNA methylation by dimethyl sulfoxide and methionine sulfoxide triggered by hydroxyl radical and implications for epigenetic modifications
Pyoderma gangrenosum was reported in one case after dulaglutide administration